msb0010841
mAbexperimental
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
7
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02156466)
Timeline
Indications
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- m1095
- msb0010841
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07223138 | Phase 3 | Oct 20, 2025 | MoonLake Immunotherapeutics AG |
| NCT07007637 | Phase 3 | Jun 27, 2025 | MoonLake Immunotherapeutics AG |
| NCT06994936 | Phase 1 | Jun 5, 2025 | MoonLake Immunotherapeutics AG |
| NCT06768671 | Phase 3 | Dec 30, 2024 | MoonLake Immunotherapeutics AG |
| NCT06641076 | Phase 3 | Oct 15, 2024 | MoonLake Immunotherapeutics AG |
| NCT06641089 | Phase 3 | Oct 15, 2024 | MoonLake Immunotherapeutics AG |
| NCT06411899 | Phase 3 | May 15, 2024 | MoonLake Immunotherapeutics AG |
| NCT06411379 | Phase 3 | May 14, 2024 | MoonLake Immunotherapeutics AG |
| NCT05640245 | Phase 2 | Dec 31, 2022 | MoonLake Immunotherapeutics AG |
| NCT05322473 | Phase 2 | Apr 25, 2022 | MoonLake Immunotherapeutics AG |
| NCT03384745 | Phase 2 | Jul 31, 2018 | Avillion, Probity Medical Research |
| NCT02156466 | Phase 1 | Aug 1, 2014 | Merck KGaA |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics AG | For profit | 10 | 10 | 3 | 2022 |
| Avillion | For profit | 1 | 1 | 1 | 2018 |
| Merck KGaA | For profit | 1 | 1 | 1 | 2014 |
| Probity Medical Research | For profit | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1